ATE466009T1 - Ccr5 antagonisten verwendbar für die behandlung von aids - Google Patents
Ccr5 antagonisten verwendbar für die behandlung von aidsInfo
- Publication number
- ATE466009T1 ATE466009T1 AT05009882T AT05009882T ATE466009T1 AT E466009 T1 ATE466009 T1 AT E466009T1 AT 05009882 T AT05009882 T AT 05009882T AT 05009882 T AT05009882 T AT 05009882T AT E466009 T1 ATE466009 T1 AT E466009T1
- Authority
- AT
- Austria
- Prior art keywords
- aids
- treatment
- ccr5 antagonists
- antagonists usable
- usable
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27993801P | 2001-03-29 | 2001-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE466009T1 true ATE466009T1 (de) | 2010-05-15 |
Family
ID=23070981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05009882T ATE466009T1 (de) | 2001-03-29 | 2002-03-27 | Ccr5 antagonisten verwendbar für die behandlung von aids |
| AT02725381T ATE299139T1 (de) | 2001-03-29 | 2002-03-27 | Ccr5 antagonisten verwendbar für die behandlung von aids |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02725381T ATE299139T1 (de) | 2001-03-29 | 2002-03-27 | Ccr5 antagonisten verwendbar für die behandlung von aids |
Country Status (29)
| Country | Link |
|---|---|
| US (5) | US6720325B2 (enExample) |
| EP (2) | EP1373256B1 (enExample) |
| JP (2) | JP4248251B2 (enExample) |
| KR (1) | KR100613528B1 (enExample) |
| CN (1) | CN100519554C (enExample) |
| AR (1) | AR033452A1 (enExample) |
| AT (2) | ATE466009T1 (enExample) |
| AU (1) | AU2002255947B8 (enExample) |
| BR (1) | BR0208398A (enExample) |
| CA (1) | CA2442227C (enExample) |
| CZ (1) | CZ20032636A3 (enExample) |
| DE (2) | DE60204951T2 (enExample) |
| DK (1) | DK1373256T3 (enExample) |
| ES (2) | ES2342942T3 (enExample) |
| HU (1) | HUP0400349A3 (enExample) |
| IL (1) | IL157551A0 (enExample) |
| MX (1) | MXPA03008853A (enExample) |
| MY (1) | MY128609A (enExample) |
| NO (1) | NO326349B1 (enExample) |
| NZ (1) | NZ527768A (enExample) |
| PE (1) | PE20020996A1 (enExample) |
| PL (1) | PL364560A1 (enExample) |
| PT (1) | PT1373256E (enExample) |
| RU (1) | RU2316553C2 (enExample) |
| SI (1) | SI1373256T1 (enExample) |
| SK (1) | SK287521B6 (enExample) |
| TW (1) | TWI237638B (enExample) |
| WO (1) | WO2002079194A1 (enExample) |
| ZA (1) | ZA200307474B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2342942T3 (es) * | 2001-03-29 | 2010-07-19 | Schering Corporation | Antagonistas de ccr5 utiles para el tratamiento del sida. |
| DK1404667T3 (da) | 2001-07-02 | 2006-07-10 | Astrazeneca Ab | Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet |
| SE0200843D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| SE0200844D0 (sv) | 2002-03-19 | 2002-03-19 | Astrazeneca Ab | Chemical compounds |
| US7132539B2 (en) | 2002-10-23 | 2006-11-07 | The Procter & Gamble Company | Melanocortin receptor ligands |
| DE60324014D1 (de) * | 2002-12-13 | 2008-11-20 | Smithkline Beecham Corp | Heterocyclische verbindungen alsccr5-antagonisten |
| PE20040769A1 (es) * | 2002-12-18 | 2004-11-06 | Schering Corp | Derivados de piperidina utiles como antagonisas ccr5 |
| SE0300957D0 (sv) | 2003-04-01 | 2003-04-01 | Astrazeneca Ab | Chemical compounds |
| CA2544377A1 (en) * | 2003-11-03 | 2005-05-12 | Schering Corporation | Bipiperidinyl derivatives useful as inhibitors of chemokine receptors |
| ES2324224T3 (es) * | 2004-02-05 | 2009-08-03 | Schering Corporation | Derivados de piperidina que se pueden utilizar como antagonistas ccr3. |
| SE0400925D0 (sv) * | 2004-04-06 | 2004-04-06 | Astrazeneca Ab | Chemical compounds |
| US7678798B2 (en) | 2004-04-13 | 2010-03-16 | Incyte Corporation | Piperazinylpiperidine derivatives as chemokine receptor antagonists |
| PE20060598A1 (es) * | 2004-09-13 | 2006-08-21 | Ono Pharmaceutical Co | Derivado heterociclo conteniendo nitrogeno como antagonista de quimiocina ccr5 |
| US7635698B2 (en) | 2004-12-29 | 2009-12-22 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| JP2008526862A (ja) * | 2005-01-06 | 2008-07-24 | シェーリング コーポレイション | ピペラジン化合物の薬学的な塩の調製 |
| JP2008526863A (ja) * | 2005-01-06 | 2008-07-24 | シェーリング コーポレイション | Ｃｃ５ｒ受容体アンタゴニストの合成 |
| AU2006216731A1 (en) * | 2005-02-23 | 2006-08-31 | Schering Corporation | Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors |
| JP4822367B2 (ja) * | 2005-02-23 | 2011-11-24 | シェーリング コーポレイション | ケモカイン受容体のインヒビターとして有用なピペリジニルピペリジン誘導体 |
| KR20080037655A (ko) | 2005-07-21 | 2008-04-30 | 아스트라제네카 아베 | 신규 피페리딘 유도체 |
| US7462485B2 (en) * | 2005-10-07 | 2008-12-09 | Glaser Lawrence F | Modified erythrocytes and uses thereof |
| TW200745087A (en) * | 2006-02-24 | 2007-12-16 | Schering Corp | CCR5 antagonists useful for treating HIV |
| US20080108586A1 (en) * | 2006-09-06 | 2008-05-08 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| JP2010513521A (ja) * | 2006-12-22 | 2010-04-30 | シェーリング コーポレイション | ４−置換１−シクロプロパン−スルホニル−ピペリジニル化合物を利用する、ｃｃｒ−５レセプターアンタゴニストを調製するためのプロセス |
| WO2009111218A2 (en) * | 2008-02-29 | 2009-09-11 | Schering Corporation | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5368854A (en) | 1992-08-20 | 1994-11-29 | Schering Corporation | Use of IL-10 to treat inflammatory bowel disease |
| AU6135294A (en) | 1993-02-12 | 1994-08-29 | Merck & Co., Inc. | Piperazine derivatives as hiv protease inhibitors |
| IL117149A0 (en) | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US5889006A (en) | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| ES2182993T3 (es) | 1995-06-07 | 2003-03-16 | Kimberly Clark Co | Inhibicion de exoproteinas en articulos absorbentes. |
| NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| TW531537B (en) | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| US5952349A (en) | 1996-07-10 | 1999-09-14 | Schering Corporation | Muscarinic antagonists for treating memory loss |
| US5977138A (en) | 1996-08-15 | 1999-11-02 | Schering Corporation | Ether muscarinic antagonists |
| AU8576098A (en) | 1997-07-25 | 1999-02-16 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| US6066636A (en) | 1998-06-30 | 2000-05-23 | Schering Corporation | Muscarinic antagonists |
| EP1013276A1 (en) * | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| EP1175402B1 (en) | 1999-05-04 | 2005-07-20 | Schering Corporation | Piperidine derivatives useful as ccr5 antagonists |
| CZ20013940A3 (cs) * | 1999-05-04 | 2002-04-17 | Schering Corporation | Piperazinové deriváty uľitečné jako CCR5 antagonisté |
| ES2342942T3 (es) * | 2001-03-29 | 2010-07-19 | Schering Corporation | Antagonistas de ccr5 utiles para el tratamiento del sida. |
-
2002
- 2002-03-27 ES ES05009882T patent/ES2342942T3/es not_active Expired - Lifetime
- 2002-03-27 EP EP02725381A patent/EP1373256B1/en not_active Expired - Lifetime
- 2002-03-27 BR BR0208398-1A patent/BR0208398A/pt not_active IP Right Cessation
- 2002-03-27 PE PE2002000251A patent/PE20020996A1/es not_active Application Discontinuation
- 2002-03-27 SK SK1196-2003A patent/SK287521B6/sk not_active IP Right Cessation
- 2002-03-27 CZ CZ20032636A patent/CZ20032636A3/cs unknown
- 2002-03-27 DE DE60204951T patent/DE60204951T2/de not_active Expired - Lifetime
- 2002-03-27 KR KR1020037012565A patent/KR100613528B1/ko not_active Expired - Fee Related
- 2002-03-27 NZ NZ527768A patent/NZ527768A/en unknown
- 2002-03-27 JP JP2002577819A patent/JP4248251B2/ja not_active Expired - Fee Related
- 2002-03-27 AT AT05009882T patent/ATE466009T1/de not_active IP Right Cessation
- 2002-03-27 IL IL15755102A patent/IL157551A0/xx not_active IP Right Cessation
- 2002-03-27 EP EP05009882A patent/EP1591444B1/en not_active Expired - Lifetime
- 2002-03-27 AT AT02725381T patent/ATE299139T1/de active
- 2002-03-27 DK DK02725381T patent/DK1373256T3/da active
- 2002-03-27 DE DE60236218T patent/DE60236218D1/de not_active Expired - Lifetime
- 2002-03-27 WO PCT/US2002/009491 patent/WO2002079194A1/en not_active Ceased
- 2002-03-27 PT PT02725381T patent/PT1373256E/pt unknown
- 2002-03-27 US US10/107,940 patent/US6720325B2/en not_active Expired - Lifetime
- 2002-03-27 MX MXPA03008853A patent/MXPA03008853A/es active IP Right Grant
- 2002-03-27 AU AU2002255947A patent/AU2002255947B8/en not_active Ceased
- 2002-03-27 PL PL02364560A patent/PL364560A1/xx not_active IP Right Cessation
- 2002-03-27 SI SI200230169T patent/SI1373256T1/sl unknown
- 2002-03-27 CN CNB028076540A patent/CN100519554C/zh not_active Expired - Fee Related
- 2002-03-27 CA CA002442227A patent/CA2442227C/en not_active Expired - Fee Related
- 2002-03-27 AR ARP020101142A patent/AR033452A1/es unknown
- 2002-03-27 RU RU2003131879/04A patent/RU2316553C2/ru not_active IP Right Cessation
- 2002-03-27 HU HU0400349A patent/HUP0400349A3/hu unknown
- 2002-03-27 ES ES02725381T patent/ES2242856T3/es not_active Expired - Lifetime
- 2002-03-28 MY MYPI20021140A patent/MY128609A/en unknown
- 2002-03-28 TW TW091106166A patent/TWI237638B/zh active
-
2003
- 2003-09-25 ZA ZA200307474A patent/ZA200307474B/en unknown
- 2003-09-26 NO NO20034311A patent/NO326349B1/no not_active IP Right Cessation
-
2004
- 2004-02-06 US US10/773,521 patent/US6900211B2/en not_active Expired - Fee Related
- 2004-10-21 US US10/970,216 patent/US7008946B2/en not_active Expired - Fee Related
-
2005
- 2005-02-17 US US11/059,785 patent/US7060701B2/en not_active Expired - Fee Related
- 2005-10-14 US US11/250,247 patent/US7098213B2/en not_active Expired - Fee Related
-
2007
- 2007-10-26 JP JP2007279663A patent/JP2008074862A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE299139T1 (de) | Ccr5 antagonisten verwendbar für die behandlung von aids | |
| DE60218493D1 (de) | Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten | |
| ATE551340T1 (de) | Azabicyclisch- substituierte annelierte heteroaryl-verbinungen für die behandlung von krankheiten | |
| DE60108754D1 (de) | Substituierte bizyklische derivate für die behandlung von unnormalem zellwachstum | |
| ATE451921T1 (de) | Phenylindole zur behandlung von hiv | |
| DE60219292D1 (de) | Pyrazolderivate zur behandlung von hiv | |
| ATE345331T1 (de) | Verbindungen verwendbar für die behandlung von entzündungskrankheiten | |
| DE50214540D1 (de) | Stanz bei der behandlung von wunden | |
| DE60316538D1 (de) | Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen | |
| ATE266655T1 (de) | Dibenzopyrane als glucocorticoid-rezeptor- antagonisten für die behandlung von zuckerkrankheit | |
| ATE418554T1 (de) | 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen | |
| ATE371451T1 (de) | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie | |
| DE60239558D1 (de) | Kombinationen für die behandlung von immun-entzündlichen erkrankungen | |
| ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
| ATE422498T1 (de) | Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems | |
| DE60105614D1 (de) | Oxazinochinolone für die behandlung viraler infektionen | |
| DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| DE60201440D1 (de) | Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression | |
| ATE345818T1 (de) | S-methyl-dihydro-ziprasidone zur behandlung von psychiatrischen störungen. | |
| ATE357441T1 (de) | Substituierte 2-pyrrolidin-2-yl-1h-indol- derivative für die behandlung von migräne | |
| DE60025403D1 (de) | Kit zur behandlung von malaria die chloroquin und bulaquin enthält | |
| ATE335500T1 (de) | Die verwendung von antagonisten des bradykinin-b2 rezeptors zur behandlung von osteoarthrose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |